PYXS on Nasdaq

Pyxis Oncology, Inc.

Pyxis Oncology is a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients with solid tumors with an immediate focus on head and neck.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with CV Sciences, Inc., Arbutus Biopharma or Opus Genetics, Inc., or pick any stock.

  • TickerPYXS on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersBoston, Massachusetts1
  • Incorporated inDE2
  • Business address321 Harrison Avenue, Boston, Ma 021182
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Pyxis Oncology is a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC).3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-609.2%Operating margin4
-574.5%Net margin4
-14.2%Revenue growth, 20254
-149.1%Return on equity4
-$63.5MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Sale of Royalty Rights brought in 80% of the revenue Pyxis Oncology, Inc. broke down this way in fiscal 2025.

  1. Sale of Royalty Rights$11.0M480%up 38% from 2024
  2. Milestone Revenue$2.8M420%
Products and services by year
Products and services20242025
Sale of Royalty Rights$8.0M$11.0M
Milestone Revenue$0$2.8M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue3¢$2.4M
  • Research and development95¢$73.7M
  • Income tax2¢$1.4M

Out of $13.9M in revenue.4 The company lost money this year.

Financial statements

Revenue4$13.9M in 2025−14% since 2024
0$5.0M$10.0M$15.0M$20.0M2024: $16.1M$16.1M20242025: $13.9M$13.9M2025−14%
Operating income56784-$84.4M in 2025+555% since 2020
-$150.0M-$100.0M-$50.0M02020: -$12.9M-$12.9M20202021: -$69.7M-$69.7M2021+441%2022: -$123.5M-$123.5M2022+77%2023: -$82.2M-$82.2M2023−33%2024: -$89.5M-$89.5M2024+9%2025: -$84.4M-$84.4M2025−6%
Net income56784-$79.6M in 2025+521% since 2020
-$150.0M-$100.0M-$50.0M02020: -$12.8M-$12.8M20202021: -$76.0M-$76.0M2021+492%2022: -$120.7M-$120.7M2022+59%2023: -$73.8M-$73.8M2023−39%2024: -$77.3M-$77.3M2024+5%2025: -$79.6M-$79.6M2025+3%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenues$13.9M$16.1M
Cost of revenues$2.4M$475.0K
Research and development$73.7M$58.7M
General and administrative$22.2M$25.4M
Impairment of in-process research and development intangible asset$0$21.0M
Total costs and operating expenses$98.3M$105.6M
Loss from operations-$84.4M-$89.5M
Interest and investment income, net$3.6M$7.0M
Sublease income$2.6M$2.9M
Total other income, net$6.2M$10.0M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total-$78.2M-$79.5M
Income tax expense (benefit)$1.4M-$2.2M
Net loss-$79.6M-$77.3M
Net loss per common share - basic-$1.28-$1.32
Net loss per common share - diluted-$1.28-$1.32
Weighted average shares of common stock outstanding - basic62.1M shares58.4M shares
Weighted average shares of common stock outstanding - diluted62.1M shares58.4M shares
Net unrealized (loss) gain on marketable debt securities-$117.0K$107.0K
Other comprehensive (loss) income-$117.0K$107.0K
Comprehensive loss-$79.7M-$77.2M

Compare Pyxis Oncology, Inc. with another company

Leadership

Who has led Pyxis Oncology, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Lara Sullivan2021–2026
  2. Thomas Civik2026–now

Chair

  1. Thomas Civik2026–now

President

  1. Lara Sullivan2023–now

Chief financial officer

  1. Connealy Pamela Yanchik2021–now

Chief operating officer

  1. Ritu Shah2021
  2. Connealy Pamela Yanchik2023–now
2025
Board members and other officers (13)

Timeline

  1. Feb 5, 2026New chief executive Thomas Civik becomes CEO11
  2. Oct 7, 2021New chief executive Lara Sullivan becomes CEO12

Filings

339 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 58 major events, 125 insider forms, 40 large holders, 95 other. The latest 20:

  1. Oct 9, 2026PRE 14A EDGAR
  2. Oct 9, 2026SCHEDULE 13G/A EDGAR
  3. Oct 9, 20264/A EDGAR
  4. Oct 5, 2026SCHEDULE 13G EDGAR
  5. Oct 2, 20264 EDGAR
  6. Oct 2, 2026SCHEDULE 13G/A EDGAR
  7. Oct 1, 20268-K EDGAR
  8. Oct 1, 2026424B5 EDGAR
  9. Sep 29, 2026424B5 EDGAR
  10. Sep 29, 2026424B5 EDGAR
  11. Sep 9, 20268-K EDGAR
  12. Sep 8, 20264 EDGAR
  13. Sep 8, 20268-K EDGAR
  14. Aug 28, 2026424B2 EDGAR
  15. Aug 27, 2026EFFECT EDGAR
  16. Aug 20, 20264 EDGAR
  17. Aug 20, 2026S-3 EDGAR
  18. Aug 14, 20264 EDGAR
  19. Aug 13, 202610-Q EDGAR
  20. Aug 13, 20268-K EDGAR

The 339 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

24 open-market trades by officers, directors and large owners since October 2021: 14 buys and 10 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 30, 2026Dupont JakobDirectorSale35,000$3.06$107.1KForm 4
Apr 21, 2025HUMPHREY RACHELDirectorSale13,896$1.03$14.3KForm 4
Apr 17, 2025HUMPHREY RACHELDirectorSale200$0.97$194Form 4
Apr 14, 2025HUMPHREY RACHELDirectorSale1,400$0.97$1.4KForm 4
Nov 26, 2024Connealy Pamela AnnCFO & COOBuy88,850$1.96$174.4KForm 4
Sep 28, 2023Connealy Pamela AnnCFO & COOBuy8,000$1.87$15.0KForm 4
Sep 27, 2023Wadhane JitendraPrin Fin & Acct OfficerBuy2,500$1.87$4.7KForm 4
Sep 27, 2023Connealy Pamela AnnCFO & COOBuy6,426$1.85$11.9KForm 4
Sep 25, 2023Wadhane JitendraPrin Fin & Acct OfficerBuy5,000$1.77$8.8KForm 4
Sep 25, 2023Connealy Pamela AnnCFO & COOBuy12,000$1.67$20.0KForm 4
Sep 22, 2023Wadhane JitendraPrin Fin & Acct OfficerBuy2,500$1.74$4.3KForm 4
Sep 22, 2023Connealy Pamela AnnCFO & COOBuy5,000$1.74$8.7KForm 4
Sep 18, 2023Sullivan LaraPresident ,CEO & CMOSale8,541$2.10$17.9KForm 4
Sep 14, 2023Sullivan LaraPresident ,CEO & CMOSale100$2.25$225Form 4
Sep 13, 2023Sullivan LaraPresident ,CEO & CMOSale3,000$2.27$6.8KForm 4
Sep 12, 2023Sullivan LaraPresident ,CEO & CMOSale4,917$2.25$11.1KForm 4
Sep 11, 2023Sullivan LaraPresident ,CEO & CMOSale20,000$2.27$45.4KForm 4
Mar 17, 2023PFIZER INC10% ownerBuy1,811,594$2.76$5.0MForm 4
Mar 17, 2023PFIZER INC10% ownerBuy1,811,594$2.76$5.0MForm 4
Apr 21, 2022Chin MarkSale1,745,761$3.05$5.3MForm 4

All 24 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 75. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
GordonMD Global Investments LP10,024,909$30.2M14.6%+5,903,039
Pfizer Inc7,032,770$19.5M11.4%No change
Laurion Capital Management LP4,900,888$14.8M1.1%−96,445
Vanguard Capital Management LLC2,075,997$6.2M0.0%+42,487
Atle Fund Management AB966,459$2.9M0.8%+769,423
BlackRock, Inc.867,934$2.6M0.0%+79,095
Palo Alto Investors LP864,277$2.6M0.4%−146,233
Marshall Wace, Llp830,544$2.5M0.0%+476,127
Renaissance Technologies LLC772,232$2.3M0.0%−116,448
Geode Capital Management, LLC591,849$1.8M0.0%−6,272
Woodline Partners LP523,999$1.6M0.0%New
683 Capital Management, LLC459,367$1.4M0.1%−436,896
Jacobs Levy Equity Management, Inc428,606$1.3M0.0%−32,391
Longaeva Partners L.P.353,582$1.1M0.0%−149,632
Decheng Capital LLC326,810$983.7K0.1%No change
Vanguard Fiduciary Trust Co302,986$912.0K0.0%+2,089
Jane Street Group, LLC290,090$873.2K0.0%−14,369
State Street Corp248,837$749.0K0.0%No change
Millennium Management LLC233,004$701.3K0.0%−164,621
UBS Group AG155,217$467.2K0.0%−98,907
Bank of New York Mellon Corp133,996$403.3K0.0%No change
Northern Trust Corp123,959$373.1K0.0%+22,011
NewEdge Wealth, LLC116,006$349.2K0.0%No change
XTX Topco Ltd110,939$333.9K0.0%−89,157
Two Sigma Investments, LP83,961$252.7K0.0%+10,661

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44